Department of Physiology, University of Toronto.
Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto.
Circ Res. 2011 Oct 14;109(9):1024-1030. doi: 10.1161/CIRCRESAHA.111.250464. Epub 2011 Sep 8.
Baseline contractility of mouse hearts is modulated in a phosphatidylinositol 3-kinase-γ-dependent manner by type 4 phosphodiesterases (PDE4), which regulate cAMP levels within microdomains containing the sarcoplasmic reticulum (SR) calcium ATPase type 2a (SERCA2a).
The goal of this study was to determine whether PDE4D regulates basal cardiac contractility.
At 10 to 12 weeks of age, baseline cardiac contractility in PDE4D-deficient (PDE4D(-/-)) mice was elevated mice in vivo and in Langendorff perfused hearts, whereas isolated PDE4D(-/-) cardiomyocytes showed increased whole-cell Ca2+ transient amplitudes and SR Ca2+content but unchanged L-type calcium current, compared with littermate controls (WT). The protein kinase A inhibitor R(p)-adenosine-3',5' cyclic monophosphorothioate (R(p)-cAMP) lowered whole-cell Ca2+ transient amplitudes and SR Ca2+ content in PDE4D(-/-) cardiomyocytes to WT levels. The PDE4 inhibitor rolipram had no effect on cardiac contractility, whole-cell Ca2+ transients, or SR Ca2+ content in PDE4D(-/-) preparations but increased these parameters in WT myocardium to levels indistinguishable from those in PDE4D(-/-). The functional changes in PDE4D(-/-) myocardium were associated with increased PLN phosphorylation but not cardiac ryanodine receptor phosphorylation. Rolipram increased PLN phosphorylation in WT cardiomyocytes to levels indistinguishable from those in PDE4D(-/-) cardiomyocytes. In murine and failing human hearts, PDE4D coimmunoprecipitated with SERCA2a but not with cardiac ryanodine receptor.
PDE4D regulates basal cAMP levels in SR microdomains containing SERCA2a-PLN, but not L-type Ca2+ channels or ryanodine receptor. Because whole-cell Ca2+ transient amplitudes are reduced in failing human myocardium, these observations may have therapeutic implications for patients with heart failure.
通过 4 型磷酸二酯酶(PDE4),在磷脂酰肌醇 3-激酶-γ的依赖性下调节心脏的基础收缩性,PDE4 调节包含肌浆网(SR)钙 ATP 酶 2a(SERCA2a)的微区中的 cAMP 水平。
本研究的目的是确定 PDE4D 是否调节基础心肌收缩性。
在 10 至 12 周龄时,PDE4D 缺陷(PDE4D(-/-))小鼠的基础心脏收缩性在体内和 Langendorff 灌流心脏中升高,而分离的 PDE4D(-/-)心肌细胞显示出增加的全细胞 Ca2+瞬变幅度和 SR Ca2+含量,但与同窝对照(WT)相比,L 型钙电流不变。蛋白激酶 A 抑制剂 R(p)-腺苷-3',5' 环单磷酸硫代酯(R(p)-cAMP)将 PDE4D(-/-)心肌细胞的全细胞 Ca2+瞬变幅度和 SR Ca2+含量降低至 WT 水平。PDE4 抑制剂罗利普兰对 PDE4D(-/-)制剂的心脏收缩性、全细胞 Ca2+瞬变和 SR Ca2+含量没有影响,但增加了 WT 心肌中的这些参数,使其达到与 PDE4D(-/-)无法区分的水平。PDE4D(-/-)心肌的功能变化与 PLN 磷酸化增加有关,但与心脏ryanodine 受体磷酸化无关。罗利普兰将 WT 心肌细胞中的 PLN 磷酸化增加到与 PDE4D(-/-)心肌细胞无法区分的水平。在鼠和衰竭的人类心脏中,PDE4D 与 SERCA2a-PLN 共免疫沉淀,但不与心脏ryanodine 受体共免疫沉淀。
PDE4D 调节包含 SERCA2a-PLN 的 SR 微区中的基础 cAMP 水平,但不调节 L 型 Ca2+通道或ryanodine 受体。由于全细胞 Ca2+瞬变幅度在衰竭的人类心肌中降低,这些观察结果可能对心力衰竭患者具有治疗意义。